Hello, everyone, and how are you today? We are doing just fine, thank you, despite gloomy skies and chilly temperatures enveloping the Pharmalot campus. After all, as the recently departed Morning Mayor used to say: Every day should be unwrapped like a precious gift. And why not? On that note, time to get on with things. There is much to do, yes? So to help you on your way, here are a few items of interest. We hope you conquer the world today and, of course, please do keep us in mind when something saucy arises.

Sanofi (SNY) was charged by French authorities for failing to adequately warn patients about the risks of its Depakote epilepsy drug, which has been linked to birth defects, Reuters writes. The charges follow a three-year probe into the company, which was launched in September 2016 following legal action by victims and their families as they sought to determine whether Sanofi misled doctors and patients. Studies found that the babies of women who took the medicine while pregnant had a 10% elevated risk for congenital malformations.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy